MFS as an endpoint in clinical trials

Earlier this year, two drugs (apalutamide/Erleada and enzalutamide/Xtandi) were each approved for the treatment of non-metastatic, castration-resistant prostate cancer (nmCRPC) based on the use of metastasis-free survival (MFS) as the study endpoint in clinical trials. … READ MORE …

Pembrolizumab in treatment of advanced prostate cancer

We finally have some published data — albeit not a lot — on the use of one of the PD-1 inhibitors (pembrolizumab, also known as Keytruda) in the treatment of late-stage prostate cancer. … READ MORE …

Newest radiopharmaceutical: thorium-227 PSMA antibody

Bayer has announced a new clinical trial of the latest entry in the race for radiopharmaceuticals to treat prostate cancer, joining 177Lu PSMA-617, 225Ac PSMA-617, and 131I MIP-1095. They are trying thorium-227 attached to a PSMA antibody. … READ MORE …

Lutetium-177 PSMA-617 in Phase III (VISION) trial for treatment of mCRPC

We have just been appraised of a randomized, double-blind, multi-center, Phase III clinical trial of the targeted, radiolabeled agent 177Lu-PSMA-617 (a form of “radioligand” therapy) in the treatment of metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Preliminary data from the TRITON 2 trial of rucaparib in mCRPC

A poster presented at the ESMO meeting in Munich has just reported data from an unplanned, preliminary analysis of data from the first 85 patients (out of a scheduled total of 150 patients) enrolled in the TRITON 2 trial of the PARP inhibitor rucaparib (Rubraca) … READ MORE …

No survival benefit to debulking the prostate with radiation in first randomized clinical trial

The term “debulking” denotes the radical treatment (via prostatectomy or radiation therapy) of the cancerous prostate — lmost always in newly diagnosed patients — after distant metastases have been discovered. … READ MORE …

New trial (S1802) for treatment of men with newly diagnosed, metastatic prostate cancer

Earlier this month we had mentioned hearing about a new trial to explore whether local ablation of the primary tumor could improve the outcomes of men initially diagnosed with metastatic prostate cancer. … READ MORE …